Investing in Health, Delivering Cures
The connection between innovation and patient health
Since entering the biotech investment scene, Dreavent has actively supported emerging U.S. biopharma companies, converting cutting-edge scientific research into innovative patient treatments. The journey to success in this field is long and requires steadfastness, expertise, and financial backing, qualities Dreavent readily provides to its portfolio companies.
As life science research progresses rapidly, it uncovers a wealth of opportunities for new medical solutions. Dreavent is enthusiastic about partnering with the next wave of biopharma innovators to turn these opportunities into tangible realities.
THE DREAVENT ADVANTAGE
Experience
More than14 years in the Boston's Biotech Ecosystem
Our involvement in the Boston Biotech Forum since 2011 has been instrumental in establishing solid relationships with top executive managers and investors in the industry. This platform has allowed us to connect and engage with key figures in the local biotech and pharmaceutical sectors, fostering meaningful collaborations and insightful discussions. Through these exclusive, invite-only events, we have created a network of influential contacts, enhancing our position and influence in the biotech landscape.
Strategic Partnerships & Co-Investments
We collaborate and co-invest with leading global pharmaceutical companies, such as Eli Lilly, Merck, or Sanofi. Our network also extends to major investment groups like 5AM and Abingworth.
This privileged partnership allows us to work closely with these esteemed organizations, sharing insights and resources to mutual benefit.
Strategy
Our venture fund invests in biotech firms specializing in Oncology, Neurolgy, Cardiovascular & Metabolic, and Immunology areas, targeting sectors ripe for innovation and investment returns. With a particular focus on Immunology, we recognize its critical influence across various health conditions and its potential for pioneering new therapies. Our goal is to back biotech innovations that drive healthcare progress and address critical medical needs.
Innovation
The Dreavent Engine is a robust investment method designed for the discerning selection of investment opportunities.
This unparalleled system systematically analyzes the global biological ecosystem, a task tremendously complex for manual processes alone.
Latest News
April 16, 2024
Chimeron Bio receives NIH (NCI) Innovative Concept Award for mRNA cancer vaccine development. “We are grateful that the National Cancer Institute recognizes potential in Chimeron Bio’s unique approach to cancer vaccines with this support,” said Dr. Antonin de Fougerolles, Chimeron Board member.
Dreavent invested in Chimeron Bio in 2022.
April 05, 2024
Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting
Dreavent invested in Elicio in 2022.
April 1, 2024
Aardvark Therapeutics gearing up for $200 million IPO. Early-stage trials showed the company’s lead drug, ARD-101, suppressed hunger cravings in patients with Prader-Willi syndrome, a rare genetic form of obesity.
Dreavent invested in Aardvark Therapeutics in 2022.